Immunovant (IMVT) said Monday it appointed director Eric Venker as chief executive, succeeding Pete Salzmann, who has retired.

The company also named Tiago Girao as chief financial officer, succeeding Renee Barnett, who has stepped down from the role. Girao previously served as CFO of Telavant.

Immunovant said the changes are part of a "strategic realignment" under which Roivant Sciences (ROIV) will lead all investor relations activity of the company.

The company said it is expanding the development of IMVT-1402 into two new indications, namely Sjogren's Disease and Cutaneous Lupus Erythematosus.